Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 8,260,000 shares, an increase of 24.0% from the March 15th total of 6,660,000 shares. Based on an average trading volume of 14,600,000 shares, the short-interest ratio is currently 0.6 days. Approximately 10.9% of the company’s stock are sold short.
Analyst Upgrades and Downgrades
IVVD has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Invivyd in a research report on Wednesday, March 26th. D. Boral Capital restated a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a report on Thursday, March 20th.
Check Out Our Latest Stock Analysis on Invivyd
Institutional Trading of Invivyd
Invivyd Trading Up 10.0 %
Invivyd stock traded up $0.05 during mid-day trading on Monday, hitting $0.56. 2,616,328 shares of the company’s stock were exchanged, compared to its average volume of 4,277,600. Invivyd has a 1-year low of $0.35 and a 1-year high of $2.74. The stock has a 50 day moving average of $0.87 and a two-hundred day moving average of $0.79. The stock has a market cap of $67.30 million, a P/E ratio of -0.29 and a beta of 0.41.
Invivyd (NASDAQ:IVVD – Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10. The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $13.57 million. As a group, research analysts predict that Invivyd will post -1.64 EPS for the current fiscal year.
Invivyd Company Profile
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Featured Stories
- Five stocks we like better than Invivyd
- Financial Services Stocks Investing
- AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
- The Role Economic Reports Play in a Successful Investment Strategy
- Why Call Option Traders Are Targeting This Dividend ETF Now
- What is the FTSE 100 index?
- Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.